-
公开(公告)号：WO2005099749A2
公开(公告)日：2005-10-27
申请号：PCT/US2005/011549
申请日：2005-04-05
Applicant: CANYON PHARMACEUTICALS, INC. , YU, Cheng-Der, Tony
Inventor： YU, Cheng-Der, Tony
IPC: A61K38/54
CPC classification number: A61K38/58 , A61K2300/00
Abstract: The present invention relates generally to methods of inhibiting angiogenesis in a patient by administering an effective angiogenesis-inhibiting amount of a thrombin inhibitor, and to the treatment of disease states that result from uncontrolled cell proliferation by administering a thrombin inhibitor alone or co-administering a thrombin inhibitor with an anticancer or cytotoxic agent. Specifically, the thrombin inhibitors used in the methods of the present invention are hirudins.
Abstract translation: 本发明一般涉及通过施用有效的血管生成抑制量的凝血酶抑制剂和通过单独施用凝血酶抑制剂或共同施用治疗由不受控制的细胞增殖而引起的疾病状态来抑制患者血管生成的方法 具有抗癌剂或细胞毒性剂的凝血酶抑制剂。 具体地，本发明的方法中使用的凝血酶抑制剂是水蛭素。
-
公开(公告)号：WO2005099749A3
公开(公告)日：2006-08-03
申请号：PCT/US2005011549
申请日：2005-04-05
Applicant: CANYON PHARMACEUTICALS INC , YU CHENG-DER TONY
Inventor： YU CHENG-DER TONY
CPC classification number: A61K38/58 , A61K2300/00
Abstract: The present invention relates generally to methods of inhibiting angiogenesis in a patient by administering an effective angiogenesis-inhibiting amount of a thrombin inhibitor, and to the treatment of disease states that result from uncontrolled cell proliferation by administering a thrombin inhibitor alone or co-administering a thrombin inhibitor with an anticancer or cytotoxic agent. Specifically, the thrombin inhibitors used in the methods of the present invention are hirudins.
Abstract translation: 本发明一般涉及通过施用有效的血管生成抑制量的凝血酶抑制剂和通过单独施用凝血酶抑制剂或共同施用治疗由不受控制的细胞增殖而引起的疾病状态来抑制患者血管生成的方法 具有抗癌剂或细胞毒性剂的凝血酶抑制剂。 具体地，本发明的方法中使用的凝血酶抑制剂是水蛭素。
-
Search Results
2
records
(took 0.007 seconds)
